Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerJulie R. Brahmer, Jon M. Wigginton, Laura Q.M. Chow et al.|New England Journal of Medicine|2012Cited by 8k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A. McArthur, Axel Hauschild, Paul B. Chapman et al.|The Lancet Oncology|2014Cited by 978
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Sophie Piperno‐Neumann, Melinda Yushak et al.|New England Journal of Medicine|2021Cited by 869
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in MelanomaAdil Daud, Omid Hamid|Journal of Clinical Oncology|2016Cited by 674
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAxel Hauschild, Aleksandar Sekulić, Michael R. Migden et al.|BMC Cancer|2017Cited by 412